You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
With a €930,000 from Horizon 2020, the firm is conducting additional stories to evaluate other uses for the test, including using new specimen types and patient cohorts.
A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.
The Dublin, Ireland-based company plans to launch its new instrument by the end of 2021 and will pursue CLIA waiver in the US.
The firm’s test for detecting flu and differentiating between subtypes A and B is being launched in Europe, Asia, and South America.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The test leverages loop mediated isothermal amplification technology and enables the rapid detection of Neisseria meningitidis directly from cerebrospinal fluid samples.
The funding will be used to expand research and development as well as the firm's international distributor network.
The test is the third in the firm's line of infectious disease assays, which also includes tests for meningococcus and Group B Strep.
The assay uses loop-mediated isothermal amplification to directly detect Streptococcus agalactiae infection, a common cause of neonatal meningitis.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.